antidiabetic

(redirected from Anti-diabetic drug)
Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.
Related to Anti-diabetic drug: acarbose

antidiabetic

 [an″te-, an″ti-di″ah-bet´ik]
preventing or alleviating diabetes.
antidiabetic agent.

an·ti·di·a·bet·ic

(an'tē-dī-ă-bet'ik),
Counteracting diabetes; denoting an agent that reduces blood sugar (for example, tolbutamide, insulin).

antidiabetic

/an·ti·di·a·bet·ic/ (-di″ah-bet´ik)
1. preventing or alleviating diabetes.
2. an agent that so acts.

antidiabetic

[-dī′əbet′ik]
pertaining to an agent that prevents or relieves symptoms of diabetes.

antidiabetic

adjective Relating to an effect or agent that counters diabetes.
 
noun See Antidiabetic agent.

antidiabetic

adjective Relating to an effect or agent that counters DM noun Antidiabetic agent Any agent that improves glucose control–eg, efficiency of glucose utilization. See Diabetes mellitus, Insulin, Triglitazone.

an·ti·di·a·bet·ic

(an'tē-dī-ă-bet'ik)
Counteracting diabetes; denoting an agent that reduces blood sugar (e.g., tolbutamide, insulin).
References in periodicals archive ?
Considering the pharmacological activity profile of embelin, it is suggested that embelin he a useful diabetic modulator or adjuvant along with clinically effective anti-diabetic drugs in the treatment of type 2 diabetes mellitus and needs to be clinically evaluated on human subjects.
Currently, anti-diabetic drugs acting through inhibiting carbohydrate absorption from the intestine are usually [alpha]-glucosidase inhibitors, such as acarbose and miglitol, which inhibit the breakdown of complex carbohydrates into simple ones in order to reduce glucose absorption and hence only work with a meal containing complex carbohydrates (Bischoff, 1994; Yee and Fong, 1996).
Hyderabad-based drug manufacturer, Aurobindo Pharma declared that it is waiting for final approval from the US Food and Drug Administration (USFDA) for its generic anti-diabetic drug Metformin Hydrochloride, which it will be introducing in 500 and 750mg strengths in the United States markets.
The study showed that sustaining modest weight loss for 10 years, or taking an anti-diabetic drug over that time, can prevent or lower the incidence of diabetes.
A total of 80 subjects with screening HbA1c between 6 and 9% on a background of one oral anti-diabetic drug (OAD), or between 6 and 8.
INDUSTRY OVERVIEW Market Outlook Major Events in the DPP-IV Inhibitor Space Current and Future Analysis The Diabetic Epidemic Type-2 Diabetes Treatment - A Brief Overview of Drug Classes in Anti-Diabetic Drugs Category Rationale for Use of DPP-4 Inhibitors Comparison of Anti-Diabetic Drug Classes by HbAC1 Reduction DPP-4 Inhibitors - Complementing Existing Approaches Outlook for DPP-IV Therapies Remains Robust DPP-4 Inhibitors versus GLP-1 Receptor Agonists Distinction Between GLP-1 Receptor Agonists and DPP-4 Inhibitors Hunt for Novel Therapeutic Areas Attracts Pharma to DPP-4 Market Limited Efficacy Drives Use of Combination Products
Washington, Aug 2 (ANI): A commonly prescribed anti-diabetic drug can reduce an individual's risk of developing pancreatic cancer by 62 percent, according to a new study.
London, June 5 (ANI): An anti-diabetic drug can increase the potency of anti-cancer vaccines by boosting the immune system, a new study has found.
London, June 4 (ANI): A widely used anti-diabetic drug, called metformin, may boost the immune system and increase the potency of vaccines and cancer treatments, say researchers at McGill University and the University of Pennsylvania.
If, as these findings suggest, there is a system in the brain that can control blood-glucose directly, it offers hope for the identification of novel anti-diabetic drug targets," Bjorbaek added.
Non-Insulin Anti-Diabetic Drug Prescriptions, 2010 69
These findings by researchers at Washington University School of Medicine, in collaboration with colleagues at the University of Michigan and MSDC, suggest that MSDC-0602, a novel anti-diabetic drug which is in Phase 2 clinical trials, may constitute the first in a class of next generation insulin sensitizers that appear to work through a new biochemical mechanism to treat insulin resistance and type 2 diabetes.

Full browser ?